Significant positive changes in fundamentals have recently occurred for Sarepta Therapeutics Inc (NASDAQ: SRPT): the consensus estimate for December, 2024 increased significantly, significant quarterly sales acceleration occurred, and the consensus estimate for December, 2025 increased significantly.
Significant positive changes in investment behavior have recently occurred for Sarepta Therapeutics Inc (NASDAQ: SRPT): the stock’s recent price rise disrupted its longer term downtrend.
In light of these very positive signals we are reviewing our current Overall Rating of A. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
SRPT is expected to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Sarepta Therapeutics has a current Value Trend Rating of A (Highest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Sarepta Therapeutics has a very high Power Rating of 88 and a very high Appreciation Score of 88, leading to the Highest Value Trend Rating.
Recent Price Action
On 7/15/24, Sarepta Therapeutics Inc (NASDAQ: SRPT) stock rose modestly by 0.4%, closing at $152.67. However, trading volume in this advance was exceptionally low at 47% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 0.6% during the last week.
Be the first to comment